S2Medical Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Petter Sivlér

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	11.8yrs
Participación del CEO	0.001%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	2.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Petter Sivlér (39 yo)

11.8yrs

Permanencia

Mr. Petter Sivlér Co-Founded S2Medical AB (publ) and has been its Chief Executive Officer from 2013.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mårten Skog	Co-Founder	11.8yrs	sin datos	sin datos
Fredrik Skog	Chair of the Board	2.9yrs	sin datos	0.0094% € 23.6
Miles Wright	Director	2.9yrs	sin datos	sin datos
Chadi Asaad	Director	2.9yrs	sin datos	sin datos
Patrick Sheehan	Director	2.9yrs	sin datos	sin datos

2.9yrs

Permanencia media

Junta con experiencia: La junta directiva de S21 no se considera experimentada (2.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.

S2Medical Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

S2Medical AB (publ), Annual General Meeting, Jun 07, 2024

No independent directors

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

No independent directors

Recent updates

New major risk - Revenue size

Second quarter 2024 earnings released

First quarter 2024 earnings released

S2Medical AB (publ), Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: kr0.082 loss per share (vs kr1.24 loss in FY 2022)

New major risk - Shareholder dilution

Third quarter 2023 earnings released

Second quarter 2023 earnings released

S2Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

New major risk - Shareholder dilution

First quarter 2023 earnings released

Full year 2022 earnings released: kr1.15 loss per share (vs kr1.35 loss in FY 2021)

S2Medical AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

S2Medical AB (publ) Announces the Positive Outcome of Antimicrobial Peptides Tests Against the Multi Resistant Bacteria

No independent directors

Third quarter 2022 earnings released

EPO Announces Intention to Approve Patenting of S2Medical AB's AMP Technology

S2Medical AB Announces Positive outcome from evaluation of Epiprotect in Saudi Arabia

S2Medical AB (publ) Updates Instagraft-Patent Approval in Israel

S2Medical AB (publ) Receives the Response from the European Patent Office That They Intend to Grant Patent Protection for the Company's Instagraft Technology Within Around Forty European Countries

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released

First quarter 2021 earnings released

New 90-day low: €0.69

New 90-day low: €0.76

S2Medical AB (publ) (OM:S2M) entered into an agreement to acquire Curenc AB.

New 90-day high: €0.90

Earnings released

New 90-day high - €0.86

CEO

Permanencia

Miembros de la Junta

Permanencia media